- In October 2022, Alliance Pharmaceuticals launched a clinical trial in collaboration with South Florida Family Health and Research Centers to evaluate the safety and efficacy of Vamousse Spray 'n' Go. This trial compares the spray to a 1% Permethrin control shampoo for treating head lice infestations. The study aims to deliver crucial insights into the effectiveness of Vamousse Spray 'n' Go, potentially positioning it as a valuable alternative or enhancement to current lice treatment options
- In September 2022, the American Academy of Pediatrics updated its guidelines for the identification and treatment of head lice. The revisions included the introduction of new medications for effective treatment and presented a clear algorithm for managing affected patients. These updates aim to enhance clarity on diagnosis and treatment options for head lice infestations
- In August 2021, ParaPRO, a specialty pharmaceutical company, announced the launch of Natroba (spinosad) Topical Suspension, 0.9%, marking the first FDA-approved treatment for scabies. This approval signifies a significant advancement in scabies therapy by offering a targeted topical option. The introduction of Natroba enhances the company’s product portfolio and strengthens its position in the market
- In October 2021, Lice Clinics of America announced the successful completion of 750,000 head lice treatments using heated air technology, achieving a remarkable 95% success rate. This innovative approach has positioned the clinics as a leading option for effective lice removal. The high success rate highlights the effectiveness of their treatment method in combating head lice infestations
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Pediculosis Capitis, Pediculosis Corporis, Pediculosis Pubis, and Others), Treatment (Ivermectin, Spinosad, Permethrin, Pyrethrin, and Other), Route of Administration (Oral, Topical, and Others), Dosage Form (Tablets, Shampoos, lotions, cream, and Others), End-Users (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) – Industry Trends and Forecast to 2031
.
The Global Lice Treatment Market size was valued at USD 106.31 USD Billion in 2023.
The Global Lice Treatment Market is projected to grow at a CAGR of 6.65% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
